User shares new hair growth stack including oral minox, daily rolling with minox application, niacin, and Dutasteride. Excited about progress and plans to update in two months.
South Korea's president is advocating for hereditary hair loss to be covered by national health insurance due to its impact on mental health and daily functioning. The discussion highlights the societal pressure in South Korea regarding appearance and the potential benefits of treating hair loss to improve mental health.
The conversation discusses various factors affecting hair loss, not just DHT, and mentions treatments like Minoxidil, finasteride, and melatonin. Some users report personal experiences with these treatments and hormone tests, while others speculate on the role of hormones like prolactin and cortisol in hair loss.
The user has been using a hair loss treatment regimen including RU58841, minoxidil, and dutasteride, but still experiences hairline recession and fatigue despite high testosterone levels. They are considering adjusting their dutasteride dosage due to concerns about libido and energy levels.
A 20-year-old is experiencing hair loss and has low levels of Vitamin D, B12, and iron. They are seeking advice on vitamin D supplementation, despite no family history of hair loss.
The user started using finasteride, minoxidil, and biotin on January 22nd and shared their hair regrowth results. They have a 4C hair type and are taking these treatments daily while exercising twice a week.
User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.
User hears aunt's comment on hair loss during Easter gathering. Others discuss handling rude comments and share experiences with hair loss treatments like Minoxidil and Finasteride.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.